encorafenib (Mektovi)

From Aaushi
Jump to navigation Jump to search

Introduction

FDA approved June 2018

Indications

Dosage

  • 50-75 mg PO

Capsules: 50 mg. 75 mg

Adverse effects

Mechanism of action

More general terms

Component of

References

  1. RxNorm
  2. Wikipedia: Encorafenib https://en.wikipedia.org/wiki/Encorafenib
  3. 3.0 3.1 Dummer R, Ascierto PA, Gogas HJ et al Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):603-615. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29573941

Database